Cargando…

1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients

BACKGROUND: Histoplasmosis in transplant recipients is understudied. We reviewed a large cohort of histoplasmosis in patients with solid organ and stem cell transplants in an endemic area to describe the epidemiology, clinical findings and outcomes. METHODS: We performed a single-center retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutjanawech, Sasinuch, Larson, Lindsey, Franklin, Alexander, Hendrix, Michael Joshua, Powderly, William, Spec, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776499/
http://dx.doi.org/10.1093/ofid/ofaa439.1271
_version_ 1783630698166353920
author Rutjanawech, Sasinuch
Larson, Lindsey
Franklin, Alexander
Hendrix, Michael Joshua
Powderly, William
Spec, Andrej
author_facet Rutjanawech, Sasinuch
Larson, Lindsey
Franklin, Alexander
Hendrix, Michael Joshua
Powderly, William
Spec, Andrej
author_sort Rutjanawech, Sasinuch
collection PubMed
description BACKGROUND: Histoplasmosis in transplant recipients is understudied. We reviewed a large cohort of histoplasmosis in patients with solid organ and stem cell transplants in an endemic area to describe the epidemiology, clinical findings and outcomes. METHODS: We performed a single-center retrospective cohort study of patients diagnosed with histoplasmosis between 2002 and 2017. Demographic data, clinical findings, diagnostic methods, treatment, and mortality were collected. We compared the characteristics of patients with history of transplant to non-transplant (NT) patients. RESULTS: We identified 261 patients with histoplasmosis. Of those, 28(11%) were transplant recipients; 8(29%) liver, 8(29%) lung, 6(21%) kidney, 3(11%) heart, and 3(11%) stem cell. Median time from symptom onset to diagnosis was 6 vs 34 days in transplant vs NT groups (p=0.001). Lung was the most common organ involvement (89% in transplants vs 78% in NT, p=0.168). Spleen involvement was more commonly found in transplant patients (29 vs 14%, p=0.039). In patients with disseminated disease, urine antigen was 100% sensitive in transplant patients compared to 78% in the NT group (p=0.038). Duration of treatment was 13 vs 6 months in transplant vs NT patients (p= 0.003). Mortality was comparable between groups (14 vs 15% in transplant vs NT, p=0.918). Median time from transplant to diagnosis was 4.21 years. However, five patients (18%) developed histoplasmosis within 6 months. For these early diagnosed patients, ICU admission rate was 80 vs 30% (p=0.04) and rate of mechanical ventilator use was 80 vs 22% (p=0.011) compared to patients diagnosed later. Table 1: Patient characteristics [Image: see text] Table 2: Organ involvement [Image: see text] Table 3: Diagnostic test positivity [Image: see text] CONCLUSION: Transplant recipients with histoplasmosis are likely to be diagnosed early and be treated longer. Urine antigen is highly sensitive for diagnosis of disseminated disease. Histoplasmosis that occurs within the first 6 months after transplantation tends to be more severe. DISCLOSURES: Andrej Spec, MD, MSCI, Astellas (Grant/Research Support)Mayne (Consultant)Scynexis (Consultant)
format Online
Article
Text
id pubmed-7776499
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77764992021-01-07 1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients Rutjanawech, Sasinuch Larson, Lindsey Franklin, Alexander Hendrix, Michael Joshua Powderly, William Spec, Andrej Open Forum Infect Dis Poster Abstracts BACKGROUND: Histoplasmosis in transplant recipients is understudied. We reviewed a large cohort of histoplasmosis in patients with solid organ and stem cell transplants in an endemic area to describe the epidemiology, clinical findings and outcomes. METHODS: We performed a single-center retrospective cohort study of patients diagnosed with histoplasmosis between 2002 and 2017. Demographic data, clinical findings, diagnostic methods, treatment, and mortality were collected. We compared the characteristics of patients with history of transplant to non-transplant (NT) patients. RESULTS: We identified 261 patients with histoplasmosis. Of those, 28(11%) were transplant recipients; 8(29%) liver, 8(29%) lung, 6(21%) kidney, 3(11%) heart, and 3(11%) stem cell. Median time from symptom onset to diagnosis was 6 vs 34 days in transplant vs NT groups (p=0.001). Lung was the most common organ involvement (89% in transplants vs 78% in NT, p=0.168). Spleen involvement was more commonly found in transplant patients (29 vs 14%, p=0.039). In patients with disseminated disease, urine antigen was 100% sensitive in transplant patients compared to 78% in the NT group (p=0.038). Duration of treatment was 13 vs 6 months in transplant vs NT patients (p= 0.003). Mortality was comparable between groups (14 vs 15% in transplant vs NT, p=0.918). Median time from transplant to diagnosis was 4.21 years. However, five patients (18%) developed histoplasmosis within 6 months. For these early diagnosed patients, ICU admission rate was 80 vs 30% (p=0.04) and rate of mechanical ventilator use was 80 vs 22% (p=0.011) compared to patients diagnosed later. Table 1: Patient characteristics [Image: see text] Table 2: Organ involvement [Image: see text] Table 3: Diagnostic test positivity [Image: see text] CONCLUSION: Transplant recipients with histoplasmosis are likely to be diagnosed early and be treated longer. Urine antigen is highly sensitive for diagnosis of disseminated disease. Histoplasmosis that occurs within the first 6 months after transplantation tends to be more severe. DISCLOSURES: Andrej Spec, MD, MSCI, Astellas (Grant/Research Support)Mayne (Consultant)Scynexis (Consultant) Oxford University Press 2020-12-31 /pmc/articles/PMC7776499/ http://dx.doi.org/10.1093/ofid/ofaa439.1271 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Rutjanawech, Sasinuch
Larson, Lindsey
Franklin, Alexander
Hendrix, Michael Joshua
Powderly, William
Spec, Andrej
1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients
title 1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients
title_full 1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients
title_fullStr 1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients
title_full_unstemmed 1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients
title_short 1085. Epidemiology and Outcomes of Histoplasmosis in Transplant Recipients
title_sort 1085. epidemiology and outcomes of histoplasmosis in transplant recipients
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776499/
http://dx.doi.org/10.1093/ofid/ofaa439.1271
work_keys_str_mv AT rutjanawechsasinuch 1085epidemiologyandoutcomesofhistoplasmosisintransplantrecipients
AT larsonlindsey 1085epidemiologyandoutcomesofhistoplasmosisintransplantrecipients
AT franklinalexander 1085epidemiologyandoutcomesofhistoplasmosisintransplantrecipients
AT hendrixmichaeljoshua 1085epidemiologyandoutcomesofhistoplasmosisintransplantrecipients
AT powderlywilliam 1085epidemiologyandoutcomesofhistoplasmosisintransplantrecipients
AT specandrej 1085epidemiologyandoutcomesofhistoplasmosisintransplantrecipients